Fig. 1From: Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancersDecision tree for the nintedanib dose escalation (A) and the collection of biological samples for ancillary analysis (B)Back to article page